November 21, 2018
AbbVie said on November 20 that it has submitted a new drug application for its oral BCL-2 (B-cell lymphoma-2) inhibitor venetoclax for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). The application is based on the results of a PI/II...read more